Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 8Breast 3Thoracic 2Other hematologic neoplasm 2Gynecologic 2Dermatologic 2Tumor-Agnostic 1Myeloid 1Genitourinary 1CNS 1

Conditions

Ovarian Neoplasms 2Breast Neoplasms 2

Interventions

Paclitaxel 268Carboplatin 264Cisplatin 194Bevacizumab 135pembrolizumab 99Surveys and Questionnaires 84Radiotherapy 77Cyclophosphamide 75olaparib 67Blood Specimen Collection 65Drug Therapy 62Hyperthermic Intraperitoneal Chemotherapy 60Gemcitabine 60niraparib 56Topotecan 56Brachytherapy 54liposomal doxorubicin 52Taxes 47Docetaxel 46Magnetic Resonance Spectroscopy 43Letrozole 36Cytoreduction Surgical Procedures 36Filgrastim 33Biopsy 33Surgical Procedures, Operative 32durvalumab 31Specimen Handling 31Doxorubicin 31Nivolumab 30Albumin-Bound Paclitaxel 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × belinostat × Gynecologic × Clear all
NCT04315233 2025-04-22

CHARGE

University of Utah

Phase 1 Recruiting
34 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04703920 2025-01-23

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

University of Michigan Rogel Cancer Center

Phase 1 Completed
26 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡